company? Let’s change
that.
Don't see your company?
Create a company profileNanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. The company’s LNP technologies aim to overcome the limits of existing approaches to nucleic acid delivery, including the ability to target tissues outside the liver (extrahepatic delivery). NanoVation’s lead technology is its proprietary long-circulating LNP (lcLNP™) platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies. NanoVation partners with leading pharmaceutical and biotech companies to enable the development of genetic medicines for previously untreatable diseases. For additional information, please visit nanovationtx.com
We are a Vancouver, Canada-based biotech firm focused on developing our innovative lipid nanoparticle (LNP) delivery platform for genetic therapies. We believe our proprietary platform provides a solution to the most critical challenge to effective CRISPR-based gene therapy — the effective and safe in vivo delivery of active gene editing machinery into target tissues. We have secured the exclusive worldwide license from the University of British Columbia to our foundational technology, and continue to build out our intellectual property and patent portfolio through additional research and development. Currently, we are focused on continued development of our innovative delivery platform for therapeutic gene editing cargoes. We have undertaken key research activities to support the development of our platform, achieving significant proof of concept data for effective in vivo gene editing. We have approached our studies in a systematic way that enables us to iterate on our foundational system. We are actively using our platform to develop strategies for multiple disease indications, as well as creating new product modifications. We are excited to be part of the Vancouver biotechnology community, in a city that is rapidly emerging as one of the most vibrant innovation hubs in North America.
Brains Bioceutical Corp is a globally recognized leader in GMP-certified production of naturally-sourced Active Pharmaceutical Ingredients (API). #MadeBetter
HTuO Biosciences is a deep tech company, working at the interface of chemistry, physics and computer programming, to develop an advanced molecular simulation capable of accurately predicting the behaviour of molecules.
Virogin Biotech aims to be a global, best-in-class oncolytic virus company that creates impactful drugs for patients of the highest medical need. Our platform technology focuses on creating long-lasting antitumor immunity by capitalizing on a robust, transient antiviral immune response through a synergy with multiple payload expression. Virogin is designing a more potent oncolytic virus, expressing optimized payloads to enhance the systemic antitumor immunity in relapsed/refractory cancers. Led by our leadership team with over 25 years of experience in fundamental research, translational and clinical development of immunotherapy & oncolytic virotherapy, we are determined to bring our novel therapies for relapsed/refractory cancers to market.
AbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development.
Microbiome Insights, Inc. is a leading global provider of end-to-end services for microbiome DNA sequencing, including state-of-the-art bioinformatic analysis. The company's customized suite of services enables researchers and clinicians to easily and effectively include microbiome analysis in studies across a range of human, animal, agricultural, and environmental applications. The multidisciplinary team of researchers and knowledge leaders at the company's helm provide access to decades of expertise in traditional sciences such as ecology, microbiology, infectious diseases, and genetics. Microbiome Insights' award-winning team is committed to providing clients with fast, dependable, cost-effective results.
Avivo, a British Columbia-based preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. This innovative platform enables a world where a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Avivo’s platform will enable healthcare providers to better prioritize patients by medical urgency, spend less on management and logistics and ultimately save more lives.
An award-winning provider of the most effective, professional skin care products, Eminence Organic Skin Care is sold in leading spas in more than 60 countries around the world. Eminence Organics melds herbal craftsmanship, innovative skin rejuvenation techniques unique to Hungary and hand-picked ingredients to craft premium natural, organic and Biodynamic® skin care that is good for the earth as well as good for the skin. Eminence Organic Skin Care is proud to be a Certified B Corporation®, the leaders of the global movement using the power of business to solve social and environmental problems, held to rigorous standards of performance, accountability and transparency for our employees, our community and our customers. We plant a tree for every product sold! Visit www.eminenceorganics.com for more information.
Vesalius Cardiovascular is a Canadian medical device company founded in 2016 in Vancouver, Canada. The company specializes in designing and developing biomedical devices for the treatment of cardiovascular disease, specifically mitral valve regurgitation (MR). We are preclinical. Our devices will be introduced percutaneously (transfemoral/transseptal) to the heart, eliminating the need for open heart surgery and the related risks. The procedure can be performed by a Cardiovascular Interventionalist (Cardiologist or Cardiac Surgeon). Vesalius Cardiovascular is the result of several years of intensive private research and investigation. The inventor behind Vesalius Cardiovascular is Dr. Peter Skarsgard, a Vancouver-based Cardiac Surgeon, and Head of the Division of Cardiovascular Surgery at Vancouver General Hospital. Our Advisory Board includes some of BC’s most prominent clinicians, including: - Peter Skarsgard (MD), Cardiac Surgeon and Head of Cardiovascular Surgery at VGH - Christopher Durkin (MD), Anaesthesiologist with advanced expertise in 3D echo for intracardiac structural disease - Jacqueline Saw (MD), Interventional Cardiologist with specialized expertise in percutaneous device delivery and structural heart intervention Vesalius Cardiovascular is currently developing Calla, a biomedical device that can be introduced percutaneously (transfemoral/transseptal) to the heart, for the treatment of degenerative MR (due to mitral valve prolapse), the most common variety of MR. The principles of surgical mitral valve repair are utilized, but sternotomy, heart-lung bypass, and cardiac arrest - components of an open heart operation - are not required
Acuitas is the premier LNP (lipid nanoparticle) technology provider, enabling our partners to advance new therapeutics to address unmet clinical needs. We have developed a broad IP portfolio focussed on the use of LNP technology for nucleic acid therapeutics. This portfolio primarily encompasses novel compositions of matter but also includes novel uses of nucleic acids therapeutics. Our mission is · To provide our partners with the best LNP delivery technology for nucleic acid therapeutics · To support our partners to rapidly advance new therapeutics to address unmet medical needs · To continually innovate to maintain and strengthen our LNP technological lead Acuitas partners locally and globally with companies, academic institutes and other organizations to improve human health.
Variational AI has developed Enki, the biopharma industry's first commercially-available foundation model for small molecules. Enki is based on a novel generative AI framework invented by Variational AI that has delivered novel and selective leads to multiple biopharma partners and customers.
SaNOtize has developed and patented (issued) a Nitric Oxide Releasing Solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Target indications include treatment for strep throat, athlete's foot, infected wounds, diabetic foot ulcers, sinusitis, cold and flu and others. With antibiotic resistance increasing in the world, SaNOtize's platform technology can help fight resistance and bring a new innovating solution to fight infections.
Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body with the aim of treating currently incurable diseases such as type 1 diabetes as well as genetic and acquired liver diseases.
Gandeeva Therapeutics is a precision biotechnology company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva’s structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline targeting difficult-to-treat cancers with novel protein interaction modulators such as interfacial glues (iGlues™) and allosteric inhibitors. Gandeeva is headquartered in the Greater Vancouver area, Canada
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. We leverage our world-class delivery systems and related technologies to bring new medicines to patients who need them. We do this by selectively collaborating with leading pharma and biotech companies and fostering a culture of innovation that allows us to maintain our leadership position in the space. • Best-in-class LNP + next generation ligand conjugate technologies • First and only FDA-approved siRNA-LNP utilizes Genevant technology • Nucleic acid payload design expertise • Several hundred patents worldwide • LNP technology evaluated in more than a dozen clinical programs, representing hundreds of subjects and patients • An established leader in delivery to the liver, now focusing capabilities on other tissues and cell types • Experienced team with deep technical expertise and a track record of innovation and creative corporate partnering
WEX Pharmaceuticals Inc. is a late-stage drug development company in Vancouver, Canada dedicated to the research, development, manufacture, and commercialization of Halneuron®, a new novel non-opioid analgesic. Halneuron® is a highly selective sodium channel blocker and represents a breakthrough in painkiller technology: - Non-addictive, no withdrawal symptoms and no euphoria - No build of up of tolerance over time - A long duration of pain relief with minimal side effects - Safe for human use and tested in over 700 people to date Halneuron® is entering into Phase III clinical trials for chemotherapy-induced neuropathic pain and concurrently being tested in other pain indications.
Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy
STEMCELL Technologies is a Canadian biotechnology company that helps power leading-edge life science research around the world. Driven by our love of science and passion for quality, we are Scientists Helping Scientists—standing by our customers to provide the outstanding products, technical support, and training they need to advance their research. Scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research are among those who rely on our cell culture media, cell separation products, instruments, accessory products, and services. Since the launch of the company by Dr. Allen Eaves in 1993, STEMCELL has reinvested all profits back into the research and development of products to better support the international research community. Today, STEMCELL is the largest biotech company in Canada, with over 2000 employees globally, most with scientific or engineering degrees. Through our many regional offices, as well as our distribution centers in Vancouver, Seattle, Grenoble, and Singapore, we deliver our innovative, specialized products to more than 70 countries. At STEMCELL, we are dedicated to improving lives through advancing knowledge and scientific discovery, through our commitment to fostering diversity and inclusion in STEM and the life sciences industry, and through our investments in sustainability, community, and social responsibility. We do all this because we love science as much as you do.
Work Your Passion. Live Your Purpose.